Form 4: REGENXBIO Executive Trades Shares

REGENXBIO Chief Medical Officer Steve Pakola executed a Rule 10b5-1 plan transaction involving the acquisition and disposition of company stock.

Summary

• Steve Pakola, Chief Medical Officer of REGENXBIO Inc., engaged in a stock transaction on July 2, 2026.
• The transaction was conducted under a Rule 10b5-1 trading plan, designed to satisfy affirmative defense conditions.
• Pakola acquired 2,161 shares of common stock at a price of $7.86 per share.
• Concurrently, Pakola disposed of 2,161 shares of common stock at a price of $13.64 per share.
• Following these transactions, Pakola beneficially owns 213,009 shares of common stock directly.
• Additionally, a stock option representing the right to purchase 2,161 shares at an exercise price of $7.86 became exercisable as part of a vesting schedule.
• This option is part of a larger grant for 103,698 shares, with 25% vested on January 2, 2026, and the remainder vesting monthly over 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions executed under a pre-defined plan without indicating significant positive or negative developments for the company.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating adherence to compliance protocols.
• The Chief Medical Officer continues to hold a significant beneficial ownership of 213,009 shares directly.
• A portion of stock options has become exercisable, reflecting continued vesting and potential future equity value realization.

Negatives

• The disposal of shares at a higher price ($13.64) than the acquisition price ($7.86) suggests a net sale of equity.
• The filing does not provide context for the specific reasons behind the Rule 10b5-1 plan execution or the number of shares involved in the disposal.

Risks

• The Rule 10b5-1 plan execution could be interpreted by the market as a signal of management's intent to sell shares, potentially impacting stock price.
• The vesting schedule for stock options, while standard, means that a portion of the executive's compensation is tied to continued service and company performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a senior executive like a Chief Medical Officer is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific details of the transaction, including the acquisition and disposition prices, are key data points for market participants.

Stakeholder Impact

• Shareholders: The transaction may be observed for insights into executive confidence, though the Rule 10b5-1 plan mitigates direct signaling.
• Employees: The vesting of stock options for the Chief Medical Officer is a standard component of executive compensation.
• Management: The transaction reflects adherence to compliance procedures for executive stock dealings.

Next Steps

• Continued monitoring of Steve Pakola's beneficial ownership and any future transactions.
• Observation of the vesting schedule for the remaining stock options.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Steve Pakola, Rule 10b5-1, Stock Options, Beneficial Ownership, Insider Trading, SEC Filing, Executive Compensation